A PH2 randomized, placebo-controlled, multiple dose study to determine the safety, pharmacokinetics and efficacy of oral ifetroban in subjects with duchenne musculary dystrophy IND136895 (10/10/2018)
Ended Project Grant Awarded Last action
- Award ID
- R01FD006371
- Recipient
-
Cumberland Pharmaceuticals, Inc. UEI M2ZXA6LYJ3S5
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,166,854
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding agency
- Office of the Commissioner Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Nashville, TN 37203, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $97,112 | |
| Amendment | $0 | |
| Amendment | $769,742 | |
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R01FD006371?
R01FD006371 was awarded to Cumberland Pharmaceuticals, Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 1, 2020.
How much is award R01FD006371 worth?
$1,166,854 has been obligated on R01FD006371.
Which agency awarded R01FD006371?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD006371, with funding from Office of the Commissioner (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award